IDEAYA Biosciences (IDYA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
Annual meeting scheduled for June 16, 2026, to be held virtually for shareholders of record as of April 20, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report or Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 annual meeting or until successors are elected.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation for named executive officers.
Provision to transact other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all three proposals on the agenda.
Nominees for Class I director positions are Yujiro S. Hata, M. Garret Hampton, Ph.D., and Catherine J. Mackey, Ph.D.
Latest events from IDEAYA Biosciences
- Proxy covers director elections, auditor ratification, and executive pay, all with board support.IDYA
Proxy filing29 Apr 2026 - Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A2-negative metastatic uveal melanoma.IDYA
Study result16 Apr 2026 - Phase III darovasertib readout in uveal melanoma due soon; robust pipeline and filings ahead.IDYA
Status update13 Apr 2026 - Darovasertib nears pivotal data as part of a broad, innovative oncology pipeline targeting major unmet needs.IDYA
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Precision oncology pipeline advances with strong clinical data and $1.05B cash runway.IDYA
Corporate presentation23 Mar 2026 - Major data readout for darovasertib/crizotinib in uveal melanoma expected by end of March.IDYA
Citi’s 2026 Virtual Oncology Leadership Summit18 Feb 2026 - Strong clinical progress and improved financials, with topline trial results due March 2026.IDYA
Q4 202517 Feb 2026 - 39% response and 94% disease control achieved in MTAP-deleted NSCLC and urothelial cancer.IDYA
Study Update3 Feb 2026 - Strong clinical progress and pipeline expansion position the company for significant growth.IDYA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026